Quality of Life, Cancer Investigation, and Clinical Practice

References

• Moinpour C M, Feigl P., Metch B, et al. Quality of life endpoints in cancer clinical trials: review and recommendations. J Natl Cancer Inst, 81: 485–495
   PubMed Web of Science ®Google Scholar
• Mayfield S G, Hailey B J. Quality of life assessment in cancer clinical trials: report of the workshop on quality of life research in cancer clinical trials. National Cancer Institute, Bethesda, MD 1990
   Google Scholar
• Gotay C C, Korn E L, McCabe M S, et al. Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst 1992; 84: 575–579
   PubMed Web of Science ®Google Scholar
• Gotay C C, Korn E L, McCabe M S, et al. Building quality-of-life assessment into cancer treatment studies. Oncology 1992; 6: 25–28
   PubMedGoogle Scholar
• Yabroff K R, Linas B P, Schulman K. Evaluation of quality of life for diverse patient populations. Breast Cancer Res Treat 1996; 40: 87–104
   PubMed Web of Science ®Google Scholar
• Schipper H, Clinich J., McMurray A, et al. Measuring the quality of life of cancer patients: The Functional Living Index–Cancer: development and validation. J Clin Oncol 1984; 2: 472–482
   PubMed Web of Science ®Google Scholar
• Aaronson N K, Ahmedzai S., Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 65–75
   Google Scholar
• Cella D F, Tulsky D S, Gray G, et al. The functional assessment of cancer therapy scale. Development and validation of the general measure. J Clin Oncol 1993; 11: 570–579
   PubMed Web of Science ®Google Scholar
• McNeil B J, Weichselbaum R, Pauker S G. Tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med 1981; 305: 982–987
   PubMed Web of Science ®Google Scholar
• Torrance G W, Thomas W H, Sackett D L. A utility maximizing model for evaluation of health care programs. Health Serv Res 1971; 7: 118–133
   Google Scholar
• Feeny D, Furlong W, Barr R D, et al. A comprehensive multi-attribute system for classifying the health status of survivors of childhood cancer. J Clin Oncol 1992; 10: 923–928
   PubMed Web of Science ®Google Scholar
• Weeks J. Quality-of-Life Assessment: performance status upstaged?. J Clin Oncol 1992; 10: 1827–1829
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Gelber R D, Simes R J, et al. Costs and benefits of adjuvant therapy in breast cancer: a quality adjusted survival analysis. J Clin Oncol 1989; 7: 36–44
   PubMed Web of Science ®Google Scholar
• Glasziou P P, Simes R J, Gelber R D. Quality-adjusted survival analysis. Stat Med 1990; 9: 1259–1276
   PubMed Web of Science ®Google Scholar
• Canadian Coordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals: Canada. 1st Ed. Ottawa, 1994.
   Google Scholar
• Helgason A R, Adolfsson J, Dickman P, et al. Waning sexual function–the most important disease-specific distress for patients with prostate cancer. Br J Cancer 1996; 73: 1417–1421
   PubMed Web of Science ®Google Scholar
• Barr R D, Pai M KR, Weitzman S, et al. A multi-attribute approach to health status measurement and clinical management–illustrated by an application to brain tumors in childhood. Int J Oncol 1994; 4: 639–648
   PubMed Web of Science ®Google Scholar
• National Wilms' Tumor Study Committee. Wilms' Tumor Status Report, 1990. J Clin Oncol 1991; 9: 877–887
   PubMed Web of Science ®Google Scholar
• Kornblith A B, Herr H W, Ofman U S, et al. Quality of life of patients with prostate cancer and their spouses. Cancer 1994; 73: 2791–2802
   PubMed Web of Science ®Google Scholar
• Slevin M L. Quality of life. Philosophical question or clinical reality. Br Med J 1992; 305: 466–469
   PubMed Web of Science ®Google Scholar
• Coates A, Gebski V, Stat M, et al. Improving the quality of life during chemotherapy of advanced breast cancer: a comparison of intermittent and continuous treatment strategies. N Engl J Med 1987; 317: 1490–1495
   PubMed Web of Science ®Google Scholar
• Gelber R D, Goldhirsch A, Hurny C, et al. Quality of life in clinical trials of adjuvant therapies. JNCI Monogr 1992; 11: 127–135
   Google Scholar
• Kassa S, Mastekaasa A, Lund E. Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease. Ra-diother Oncol 1989; 15L: 235–242
   Google Scholar
• Ruchdeschel J C, Pinantadosi S. Quality of life assessment in lung surgery for bronchogenic carcinoma. J Theor Surg 1991; 6: 201–205
   Google Scholar
• Coates A, Gebski V, Signorini D, et al. Prognostic value of quality-of-life scores during chemotherapy for advance breast cancer. J Clin Oncol 1992; 10: 1833–1838
   PubMed Web of Science ®Google Scholar
• Osoba D, Zee B, Sadura A, . Measurement of quality of life in an adjuvant trial of gamma interferon versus levamisole in malignant melanoma. Adjuvant Therapy of Cancer. Vol 7, S E Salmon, et al. JB Lippincott, Philadelphia 1993; 412–416
   Google Scholar
• Loprinzi C L, Laurie J A, Wieand S, et al. Prospective evaluation of prognostic variables from patient-completed questionnaires. J Clin Oncol 1994; 12: 601–607
   PubMed Web of Science ®Google Scholar
• Sedman A D, Porteney R, Yao T J, et al. Quality of life in phase II trials: a study of methodology and predictive value in patients with advance breast cancer treated with paclitaxel plus granulocyte colony stimulating factor. J Nat Cancer Inst 1995; 87: 1316–1322
   PubMed Web of Science ®Google Scholar
• Earlam S, Glover C, Fordy C, et al. Relation between tumor size, quality of life and survival in patients with colorectal liver metastases. J Clin Oncol 1996; 14: 171–175
   PubMed Web of Science ®Google Scholar
• Cella D F, Fairclough D L, Bonomi P, et al. Quality of life in advance non-small cell lung cancer: results from Eastern Cooperative Oncology Group study 5592. Proc Am Soc Clin Oncol 1997; 16: 2a, (abstract)
   Google Scholar
• Slevin M L, Plant H, Lynch D, et al. Who should measure quality of life, the doctor or the patient?. Br J Cancer 1988; 57: 109–112
   PubMed Web of Science ®Google Scholar
• Osoba D, Zee B, Pater J, et al. Determinants of post-chemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 1997; 15: 116–123
   PubMed Web of Science ®Google Scholar
• McNeil B J, Weishelbaum R, Pauker S G. Fallacy of the five-year survival in lung cancer. N Engl J Med 1978; 299: 1397–1401
   PubMed Web of Science ®Google Scholar
• Osoba D, Rodrigues G, Myles J Z, et al. Interpreting the significance of changes in health-related quality of life scores. J Clin Oncol 1998; 16: 139–144
   PubMed Web of Science ®Google Scholar
• Osoba D. Measuring the effect of cancer on health-related quality of life. Pharmacoeconomics 1995; 7: 308–391
   PubMed Web of Science ®Google Scholar